Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0959-8049(05)80411-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Carcinosarcoma of the breast: Facing the challenge of a rare nosologic entity.
World J Clin Cases
January 2025
Department of Surgery, National and Kapodistrian University of Athens, Athens 11527, Greece.
Carcinosarcoma (CS), also known as metaplastic breast carcinoma with mesenchymal differentiation, is one of the five distinct subtypes of metaplastic breast cancer. It is considered as a mixed, biphasic neoplasm consisting of a carcinomatous component combined with a malignant nonepithelial element of mesenchymal origin without an intermediate transition zone. Although cellular origin of this neoplasm remains controversial, most researchers declare that neoplastic cells derive from a cellular structure with potential biphasic differentiation.
View Article and Find Full Text PDFPigmented Superficial Basal Cell Carcinoma of the Nipple-Areola Complex: A Case Report.
Case Rep Dermatol
January 2025
Department of Dermatology, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, PR China.
Introduction: Basal cell carcinoma (BCC) is the most common type of skin malignancy, accounting for approximately 80% of all non-melanoma skin cancers (NMSCs). Ultraviolet (UV) exposure is a significant risk factor for BCC development, which typically occurs in sun-exposed areas. BCC arising in non-sun-exposed regions, such as the nipple-areola complex (NAC), is exceedingly rare, with fewer than 100 cases reported globally.
View Article and Find Full Text PDFPredictive modeling of breast cancer-related lymphedema using machine learning algorithms.
Gland Surg
December 2024
Department of Breast Oncology, Hainan Cancer Hospital, Haikou, China.
Background: Breast cancer-related lymphedema (BCRL) is one of the common complications after breast cancer surgery. It can easily lead to limb swelling, deformation and upper limb dysfunction, which has a serious impact on the physical and mental health and quality of life of patients. Previous studies have mostly used statistical methods such as linear regression and logistic regression to analyze the influencing factors, but all of them have certain limitations.
View Article and Find Full Text PDFIntratumoral Injection of mRNA-2752 and Pembrolizumab for High-Risk Ductal Carcinoma In Situ: A Phase 1 Nonrandomized Clinical Trial.
JAMA Oncol
January 2025
Department of Surgery, University of California, San Francisco.
Importance: Intratumoral immunotherapy that leverages the biological characteristics of high-risk ductal carcinoma in situ (DCIS) may be able to reduce the extent of surgical treatment and provide an alternative approach to improve patient outcomes.
Objective: To determine if combination intratumoral immunotherapy can activate immune cells to shrink or eliminate high-risk DCIS.
Design, Setting, And Participants: This phase 1 open-label nonrandomized clinical trial at a single academic center tested the safety and efficacy of intratumoral immunotherapy in patients with high-risk DCIS, defined as at least 2 of the following present: younger than 45 years, tumor size greater than 5 cm, high-grade, palpable mass, hormone receptor (HR)-negative, or ERBB2-positive.
Axilla Management in Breast Cancer Surgery: Brief Review and Current Practice Recommendations.
Am Surg
January 2025
Department of Surgery, Rea Maternity Hospital, Athens, Greece.
The diagnostic and therapeutic approach to the axilla in breast cancer patients has changed significantly over the past 30 years, with the replacement of complete axillary lymph node dissection practices by less invasive approaches. Reference is made to clinical findings that have led to practical treatment recommendations and are paving the way to new levels of de-escalation in breast cancer surgery.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!